BMS-582949

BMS-582949 is an investigational small molecule inhibitor developed by Bristol Myers Squibb. It acts as a dual-action kinase inhibitor, specifically targeting p38 mitogen-activated protein kinase (p38 MAPK), a key regulator of inflammatory processes. The drug was primarily investigated for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, and atherosclerosis. Mechanistically, it inhibits both the activity and activation of p38 MAPK, thereby modulating cellular responses involved in inflammation. Clinical development reached Phase II trials but was discontinued for all major indications[1][2][3][7].

Other names

CR743OME9ECR-743OME9ECR 743OME9EUNII-CR743OME9EUNII-CR-743OME9EUNII-CR 743OME9E623152-17-0